Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 13/20 | 0.75 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467041 | 0.91 | NPY1R (0.70) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL7044245 | 0.84 | NPY1R (1.00) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL1593530 | 0.83 | NPY1R (0.67) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL7041260 | 0.83 | NPY1R (0.78) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL1593336 | 0.80 | NPY1R (0.79) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL1593289 | 0.80 | NPY1R (0.78) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL7039384 | 0.79 | NPY1R (0.78) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL5729134 | 0.79 | NPY1R (0.85) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL7039992 | 0.79 | NPY1R (0.79) | NPY1RCRHR1KDM4EALDH1A1MAPT | |
| SCHEMBL7110712 | 0.79 | NPY1R (0.78) | NPY1RCRHR1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION (US) | 2003-04-10 | — | — | US | claimed |
| EP-1218379-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | claimed |
| US-6372743-B1 | EATING DISORDERS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | NEUROGEN CORPORATION | 2002-04-16 | — | — | US | claimed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NPY1R, NPY5R, NPY2R | NPY1R 1/4885CRHR1 15/4885KDM4E 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.